Climb Bio CLYM 深 沪
等待开盘 05-19 09:30:00 美东时间
9.88
-0.920
-8.52%
华盛通- 最 高10.80
- 今 开10.80
- 成交量 63.47万股
- 最 低 9.6329
- 昨 收 10.80
- 总市值 5.66亿
- 52周最高 12.48
- 市盈率 静 --
- 换手率 1.11%
- 52周最低 1.16
- 委 比 -93.37%
- 总股本 5726.05万
- 历史最高 29.69
- 量 比 1.05
- 振 幅 10.81%
- 历史最低 1.05
- 每 手 1
- 风险率 2.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Climb Bio to Present at Upcoming Investor Conferences
Climb Bio, Inc. announced that its executive team members will participate in two upcoming conferences: the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19 and the Jefferies Global Healthcare Conference on June 4. Both events will feature fireside chats, and live webcasts will be available on the company’s website, with replays archived for 30 days. Climb Bio focuses on developing therapeutics for immune-mediated diseases, wit...
05-12 11:00
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Climb Bio Q1 EPS $(0.20) Beats $(0.29) Estimate
Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 35.48 percent increase over losses of $(0.31) per share from the
05-07 21:27
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
U.S. RESEARCH ROUNDUP-IBM, Lumentum Holdings, TransDigm Group
U.S. RESEARCH ROUNDUP-IBM, Lumentum Holdings, TransDigm Group May 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including IBM, Lumentum Holdings and TransDigm Group, on Wednesday. HIGHLIGHTS * Advanced Micro Devices AMD.O : Ev
05-06 15:13
美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
Chardan Capital Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $22
Chardan Capital analyst Geulah Livshits initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $22.
05-06 02:56
Climb Bio Highlights Budoprutug Progress at R&D Spotlight
The latest announcement is out from Climb Bio ( ($CLYM) ). On May 5, 2026, Clim...
05-05 20:26
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi May 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Applied Materials, Axsome Therapeutics and Onsemi on Tuesday. HIGHLIGHTS * Applied Materials AMA
05-05 15:07
